Sequential administration of chemotherapy followed by radioimmunotherapy with Iodine-131-Tositumomab in untreated non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
Kostakoglu, L
Goldsmith, SJ
Vallabhajosula, S
Coleman, M
Morris, A
Link, BK
Kaminski, MS
Nadeau, K
Valente, N
Leonard, JP
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[2] Corixa Corp, Redwood City, CA USA
[3] Univ Iowa, Ctr Canc, Iowa City, IA 52242 USA
[4] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS78
引用
收藏
页码：981 / 981
页数：1
相关论文
共 50 条
  • [41] A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with >25% bone marrow involvement.
    Mones, J
    Coleman, M
    Kostakoglu, L
    Fiore, JM
    Muss, D
    Furman, R
    Stewart, P
    Kroll, S
    Goldsmith, SJ
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [42] Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
    Press, Oliver W.
    Unger, Joseph M.
    Braziel, Rita M.
    Maloney, David G.
    Miller, Thomas P.
    LeBlanc, Michael
    Fisher, Richard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4143 - 4149
  • [43] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [44] Bexxar™ (Iodine-131 tositumomab) radio immunotherapy for patients with B-cell non-Hodgkin's lymphoma
    Micallef, I
    Radford, J
    Britten, K
    Owen, S
    Deakin, D
    Jan, H
    Foley, R
    Barlow, R
    Carrington, B
    Lawrance, J
    Vinnicombe, S
    Harris, M
    Norton, A
    Lister, A
    Rohatiner, A
    BRITISH JOURNAL OF CANCER, 2000, 83 : 16 - 16
  • [45] Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions.
    Zelenetz, A. D.
    Noy, A.
    Pandit-Taskar, N.
    Scordo, M.
    Rijo, I.
    Zhou, Y.
    O'Donoghue, J. A.
    Divgi, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 436S - 436S
  • [46] Single center experience with iodine I 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL).
    Wahl, RL
    Zasadny, KR
    Estes, J
    Kison, PV
    Regan, DD
    McCullough, NT
    Kroll, S
    Stagg, B
    Kaminski, MS
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 78P - 79P
  • [47] Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multicenter phase II study.
    Horning, SJ
    Lucas, JB
    Younes, A
    Podoloff, D
    Jain, V
    Kroll, S
    Stagg, R
    Nadeau, K
    Tidmarsh, G
    BLOOD, 2000, 96 (11) : 508A - 508A
  • [48] A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma
    Press, Oliver W.
    Unger, Joseph M.
    Rimsza, Lisa M.
    Friedberg, Jonathan
    LeBlanc, Michael
    Czuczman, Myron S.
    Kaminski, Mark S.
    Braziel, Rita M.
    Maloney, David G.
    Cheson, Bruce D.
    Miller, Thomas P.
    Fisher, Richard I.
    BLOOD, 2011, 118 (21) : 48 - 48
  • [49] Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members
    Rutar, FJ
    Augustine, SC
    Kaminski, MS
    Wahl, RL
    Siegel, JA
    Colcher, D
    CLINICAL LYMPHOMA, 2001, 2 (03): : 164 - 172
  • [50] Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with Tositumomab/Iodine I131 I-Tositumomab followed by CHOP chemotherapy results in a high complete remission rate.
    Zelenetz, AD
    Donnelly, G
    Halaas, J
    Sgouros, G
    Humm, J
    Popplewell, L
    Reyes, S
    Maignan, K
    Campbell, C
    Moskowitz, CH
    Nimer, SD
    Pandit-Taskar, N
    Divgi, C
    BLOOD, 2003, 102 (11) : 406A - 406A
12345